Radioembolization for Treatment of Salvage Patients with Colorectal Cancer Liver Metastases: A Systematic Review

Journal of Nuclear Medicine

Maurice A.A.J. van den Bosch¹  Miriam Koopman¹  Marnix G.E.H. Lam¹  Charlotte E.N.M. Rosenbaum¹  Tom van Seeters¹  Malou A. Vermoolen¹  Helena M. Verkooijen¹  Maarten L.J. Smits¹ 

关键词: radioembolization;    colorectal cancer;    liver metastases;   

DOI  :  10.2967/jnumed.113.119545

学科分类：医学（综合）

来源: Society of Nuclear Medicine

【 摘 要 】

Currently, there is no consensus on the use of 90Y radioembolization for salvage patients with colorectal cancer liver metastases. The purpose of this study was to provide a comprehensive overview of the available data on tumor response and survival after 90Y radioembolization for this group of patients. Methods: A systematic literature search was conducted in PubMed (Medline), Excerpta Medica (EMBASE), and the Cochrane Library (September 2012) with synonyms for “radioembolization” and “colorectal cancer liver metastases.” Results were described separately for patient cohorts treated with 90Y radioembolization as monotherapy and with 90Y radioembolization in combination with chemotherapy. Results: The search yielded 13 relevant articles for systematic review on 90Y radioembolization as monotherapy and 13 relevant articles on 90Y radioembolization combined with chemotherapy. Disease control rates (i.e., complete response, partial response, and stable disease) ranged from 29% to 90% for 90Y radioembolization as monotherapy and from 59% to 100% for 90Y radioembolization combined with chemotherapy. Heterogeneity in the data prohibited pooling of response rates. Survival proportions at 12 mo ranged from 37% to 59% for 90Y radioembolization as monotherapy and from 43% to 74% for 90Y radioembolization combined with chemotherapy. Conclusion: In the studies included in this systematic review, approximately 50% of salvage patients with colorectal cancer liver metastases survive more than 12 mo after treatment with 90Y radioembolization, either as monotherapy or in combination with chemotherapy. Heterogeneity between studies has unfortunately prohibited pooling of data. Future research will discern the precise role of 90Y radioembolization in general clinical practice in comparison with chemotherapy.

【 授权许可】

Unknown